Recognizing the promising clinical potential of RSPOs as novel therapeutic targets, a clinical trial has been set-up that tested the safety and efficacy of the neutralizing monoclonal anti-RSPO3 antibody OMP131-R10 (Rosmantuzumab) in cancer patients with advanced solid tumors and metastatic CRC [154]. The gene discussed is RSPO3; the disease is cancer.